A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

September 27, 2026

Study Completion Date

December 31, 2026

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG

HS-10561

Single and multiple doses of HS-10561 orally

DRUG

Placebo

Trial Locations (1)

Shanghai Hospital of Skin Disease, Shanghai